Sonoma Pharmaceuticals, Inc. · NASDAQ:SNOA

Sonoma Pharmaceuticals — Q2 FY2019 Earnings Presentation

11 slides from Sonoma Pharmaceuticals's earnings presentation, Nov 8, 2018

  1. Slide 1: Sonoma Pharmaceuticals Results for the Quarter Ended 30 September 2018

    1 NASDAQ: SNOA SONOMA PHARMACEUTICALS RESULTS FOR THE QUARTER ENDED 30 September 2018 November 8, 2018

  2. Slide 2: Agenda

    2 NASDAQ: SNOA Agenda Welcome / Introduction September Quarter 2018 Highlights Financial Review Q+A Jim Schutz Bob Miller Jim Schutz / Bob Miller / Marc Umscheid Jim Schutz

  3. Slide 3: Forward-Looking Statement

    3 NASDAQ: SNOA Forward - Looking Statement Except for historical information herein, matters set forth in this presentation are forward - looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 , including statements about the commercial and

  4. Slide 4: Results from the Quarter Ended Sep 2018

    4 NASDAQ: SNOA Results from the Quarter Ended 30 Sep 2018 4 Total Revenue = $4.9M Up 14% versus same period last year Up 13% versus the quarter ending 30 Jun 2018 EBITDA = ($1.95M) Cash as of 30 Sep 2018 = $4M

  5. Slide 5: Epicyn Antimicrobial Facial Cleanser - US

    5 NASDAQ: SNOA Epicyn Antimicrobial Facial Cleanser - US New! In January 2019

  6. Slide 6: Gramacyn - Brazil

    6 NASDAQ: SNOA Sold individually Sold as Combo pack Gramacyn - Brazil New! In November 2018

  7. Slide 7: Study Results of Randomized Clinical Trial of HOCl for Acne Lesions

    7 NASDAQ: SNOA Tirado - Sánchez A, Ponce - Olivera : Efficacy and Tolerance of Superoxidized Solution in the Treatment of Mild to Moderate Inflammatory Acne. A Double - Blinded, Placebo - Controlled, Parallel - Group, Randomized, Clinical Trial.” J Derm Treatment 20, (5) 289 – 292, 2009. Study Resul

  8. Slide 8: Quarterly Comparison of Key Financial Metrics

    8 NASDAQ: SNOA Quarterly Comparison of Key Financial Metrics Quarter Ended Quarter Ended Sept 30 , 2017 Quarter Ended June 30 , 2018 September 30 , 2018 Amount Variance  Amount Variance  Total net revenues $4,939 $4,325 $614 14  $4,369 $570 13  Product revenues $4,653 $4,144 $491 12  $4,096 $53

  9. Slide 9: Total Dispensed Prescriptions by Quarter

    9 NASDAQ: SNOA 0 1,106 2,724 3,361 4,059 3,769 4,809 5,793 6,648 5,659 5,446 6,728 7,174 6,804 5,319 6,146 7,968 0 39 1,043 2,305 3,103 2,833 3,339 4,275 4,341 3,425 3,253 4,053 4,348 4,218 3,466 3,785 4,879 0 134 476 635 526 625 970 1,326 1,771 1,916 1,491 1,514 920 0 1,084 1,725 1,656 1,381 1,294

  10. Slide 10: Factory Units Sold by Quarter

    10 NASDAQ: SNOA 0 1,106 3,573 4,963 4,274 3,008 4,190 6,201 6,827 7,175 5,712 6,757 7,327 8,383 4,807 6,576 7,808 0 39 3,068 2,580 4,284 3,571 3,382 4,298 4,405 4,204 3,488 4,914 4,938 4,930 3,082 4,214 4,567 1,092 546 582 222 318 414 921 1,217 1,733 1,699 1,185 1,245 773 0 689 1,410 1,908 1,440 1,0

  11. Slide 11: Impact of Wholesaler Inventory on Revenue

    11 NASDAQ: SNOA Impact of Wholesaler Inventory on Revenue Inventory units

Sonoma Pharmaceuticals — Q2 FY2019 Earnings Presentation on 6ix